Article in Cold Spring Harbor molecular case studies, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors at 1 institution in 1 country.
Mara W RosenbergKnight Cancer Institute, Oregon Health and Science University, Portland, Oregon 97215, USA.ORCID 0000-0001-6400-3161
Samantha L SavageKnight Cancer Institute, Oregon Health and Science University, Portland, Oregon 97215, USA.
Christopher A EideKnight Cancer Institute, Oregon Health and Science University, Portland, Oregon 97215, USA.ORCID 0000-0001-8835-8928
Anna Reister SchultzKnight Cancer Institute, Oregon Health and Science University, Portland, Oregon 97215, USA.ORCID 0000-0001-9977-7343
Rachel J CookDivision of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97215, USA.
Richard D PressKnight Cancer Institute, Oregon Health and Science University, Portland, Oregon 97215, USA.ORCID 0000-0002-2103-5144
Carole RempferKnight Cancer Institute, Oregon Health and Science University, Portland, Oregon 97215, USA.
Garrett EickelbergKnight Cancer Institute, Oregon Health and Science University, Portland, Oregon 97215, USA.ORCID 0000-0002-5732-735X
Beth WilmotKnight Cancer Institute, Oregon Health and Science University, Portland, Oregon 97215, USA.ORCID 0000-0003-3579-3592
Shannon K McWeeneyKnight Cancer Institute, Oregon Health and Science University, Portland, Oregon 97215, USA.ORCID 0000-0001-8333-6607
Jeffrey W TynerKnight Cancer Institute, Oregon Health and Science University, Portland, Oregon 97215, USA.ORCID 0000-0002-2133-0960
Brian J DrukerKnight Cancer Institute, Oregon Health and Science University, Portland, Oregon 97215, USA.ORCID 0000-0001-8331-8206
Cristina E TognonKnight Cancer Institute, Oregon Health and Science University, Portland, Oregon 97215, USA.ORCID 0000-0002-4872-3078
Oregon Health & Science University · US
Funding
Oregon Clinical and Translational Research Institute - The National COVID Cohort Collaborative (N3C)UL1TR002369 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Cynthia D Morris, Christopher G. Slatore · 2017 to 2026
$78.4M
Tumor Intrinsic and Microenvironmental Mechanisms Driving Drug Combination Efficacy and Resistance in AMLU54CA224019 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI BRIAN J DRUKER, Shannon K. McWeeney · 2017 to 2026
$13.9M
Proteogenomic Translational Research Center for Clinical ProteomicU01CA214116 · NCI · BATTELLE PACIFIC NORTHWEST LABORATORIES · PI DRUKER, BRIAN J, RODLAND, KARIN D · 2017 to 2021
$6.8M
Functional Genomic Discovery of Pathway Targeted and Immune Modulatory Therapeutic Combinations in Hematologic MalignanciesU01CA217862 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI DRUKER, BRIAN J, TYNER, JEFFREY WALLACE · 2017 to 2021
$5.3M
CHRONIC MYELOGENOUS LEUKEMIA AND BCR-ABL SUBSTRATESR01CA065823 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI DRUKER, BRIAN J · 1995 to 2021
$4.7M
An Academic-Industry Partnership to Advance Functional Genomics for Personalized Oncology.R01CA214428 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KEMP, CHRISTOPHER J · 2018 to 2022
The Philadelphia chromosome (Ph) resulting from the t(9;22) translocation generates the oncogenic BCR::ABL1 fusion protein that is most commonly associated with chronic myeloid leukemia (CML) and Ph-positive (Ph+) acute lymphoblastic leukemia (ALL). There are also rare instances of patients (≤1%) with newly diagnosed acute myeloid leukemia (AML) that harbor this translocation (Paietta et al.,
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Comprehensive molecular characterization of a rare case of Philadelphia chromosome-positive acute myeloid leukemia. · full record | OpenQuestion